Chronic kidney disease: Targeting prostaglandin E2 receptors

American Journal of Physiology - Renal Physiology

Volumn 307, Issue 3, 2014, Pages

  Nasrallah, Rania ^a   Hassouneh, Ramzi ^a   Hébert, Richard L ^a  

^a UNIVERSITY OF OTTAWA   (Canada)

Author keywords

Chronic kidney disease; Diabetic kidney; EP receptors

Indexed keywords

PROSTAGLANDIN E RECEPTOR; PROSTAGLANDIN SYNTHASE;

CHRONIC KIDNEY DISEASE; DIABETES MELLITUS; DISEASE COURSE; HUMAN; HYPERGLYCEMIA; HYPERTENSION; INFLAMMATION; KIDNEY DISEASE; OXIDATIVE STRESS; PRIORITY JOURNAL; PROTEIN TARGETING; REVIEW;

CHRONIC KIDNEY DISEASE; DIABETIC KIDNEY; EP RECEPTORS; PROSTAGLANDIN E2;

DISEASE PROGRESSION; HUMANS; HYPERGLYCEMIA; HYPERTENSION; INFLAMMATION; OXIDATIVE STRESS; RECEPTORS, PROSTAGLANDIN E; RENAL INSUFFICIENCY, CHRONIC;

EID: 84905280645     PISSN: 1931857X     EISSN: 15221466     Source Type: Journal    
DOI: 10.1152/ajprenal.00224.2014     Document Type: Review

References (119)

1. 2 receptors in the control of murine renal hemodynamics. Am J Heart Circ Physiol 280: H327-H333, 2001.
2. 2 on perfusion of rat renal cortex and medulla: interactions with the reninangiotensin system. Exp Physiol 93: 1292-1302, 2008.
3. Bek M, Nusing RM, Kowark P, Henger A, Mundel P, Pavenstadt H. Characterization of prostanoid receptors in podocytes. J Am Soc Nephrol 10: 2084-2093, 1999.
4. Boor P. EP4: a new piece in the fibrotic puzzle. Kidney Int 82: 132-135, 2012.
5. Briet M, Burns KD. Chronic kidney disease and vascular remodelling: molecular mechanisms and clinical implications. Clin Sci 123: 399-416, 2012.
6. Cavanaugh KL. Diabetes management issues for patients with chronic kidney disease. Clin Diabetes 25: 90-97, 2007.
7. Chen L, Zhang J, Zhang Y, Wang Y, Wang B. Improvement of inflammatory responses associated with NF-kappa B pathway in kidneys from diabetic rats. Inflamm Res 57: 199-204, 2008.
8. Cheng HF, Wang CJ, Moeckel GW, Zhang MZ, McKanna JA, Harris RC. Cyclooxygenase-2 inhibitor blocks expression of mediators of renal injury in a model of diabetes and hypertension. Kidney Int 62: 929-939, 2002.
9. Cherney DZI, Miller J, Scholey JW, Bradley TJ, Slorach C, Curtis J, Dekker M, Nasrallah R, Hébert RL, Sochett EB. The effect of cyclooxygenase 2 inhibition on renal hemodynamic function in humans with type 1 diabetes mellitus. Diabetes 57: 688-695, 2008.
10. Cherney DZ, Reich HN, Jiang S, Har R, Nasrallah R, Hébert RL, Lai V, Scholey JW, Sochett EB. Hyperfiltration and effect of nitric oxide inhibition on renal and endothelial function in humans with uncomplicated type 1 diabetes mellitus. Am J Physiol Regul Integr Comp Physiol 303: R710-R718, 2012.
11. Cherney DZI, Scholey JW, Nasrallah R, Dekker MG, Slorach C, Bradley TJ, Hébert RL, Sochett EB, Miller JA. Renal hemodynamic effect of cyclooxygenase 2 inhibition in young men and women with uncomplicated type 1 diabetes mellitus. Am J Physiol Renal Physiol 294: F1336-F1341, 2008.
12. Choudhury D, Tuncel M, Levi M. Diabetic nephropathy-a multifaceted target of new therapies. Discov Med 10: 406-415, 2010.
13. Claria J, Kent JD, Lopez-Parra M, Escolar G, Ruiz-del-Arbol L, Gines P, Jimenez W, Vucelic B, Arroyo V. Effects of celecoxib and naproxen on renal function in nonazotemic patients with cirrhosis and ascites. Hepatology 41: 579-587, 2005.
14. Declèves AE, Sharma K. Novel targets of antifibrotic and anti-inflammatory treatment in CKD. Nat Rev Nephrol 10: 257-267.
15. Dorrington KL, Pandit JJ. The obligatory role of the kidney in long-term arterial blood pressure control: extending Guyton's model of the circulation. Anaesthesia 64: 1218-1228, 2009.
16. Dronavalli S, Duka I, Bakris GL. The pathogenesis of diabetic nephropathy. Nat Clin Pract Endocrinol Metab 4: 444-452, 2008.
17. 2-induced cystogenesis of human renal epithelial cells. Am J Physiol Renal Physiol 293: F1622-F1632, 2007.
18. 4 receptor through a PKA independent mechanism. Cell Signal 20: 2156-2164, 2008.
19. 2 modulate critical signaling pathways in mouse podocytes. Cell Signal 22: 1222-1230, 2010.
20. 2. Am J Physiol Renal Physiol 275: F955-F961, 1998.
21. 2 synthetic system in the kidney is associated with the time frame of renal developmental vulnerability to cyclooxygenase-2 inhibition. Am J Physiol Renal Physiol 303: F209-F219, 2012.
22. 2, prostanoid receptors via the phosphatidylinositol 3-kinase and extracellular signal-regulated kinases. J Biol Chem 278: 12151-12156, 2003.
23. 2 receptor subtype 1 targeting. J Clin Invest 117: 2496-2505, 2007.
24. Gueutin V, Vallet M, Jayat M, Peti-Peterdi J, Cornière N, Leviel F, Sohet F, Wagner CA, Eladari D, Chambrey R. Renal β-intercalated cells maintain body fluid and electrolyte balance. J Clin Invest 123: 4219-4231, 2013.
25. Hall JE, Granger JP, do Carmo JM, da Silva AA, Dubinion J, George E, Hamza S, Speed J, Hall ME. Hypertension: physiology and pathophysiology. Compr Physiol 2: 2393-2442, 2012.
26. Harrison-Bernard LM, Monjure CJ, Bivona BJ. Efferent arterioles exclusively express the subtype 1A angiotensin receptor: functional insights from genetic mouse models. Am J Physiol Renal Physiol 290: F1177-F1186, 2006.
27. Hirschberg R, Wang S. Proteinuria and growth factors in the development of tubulointerstitial injury and scarring in kidney disease. Curr Opin Nephrol Hypertens 14: 43-52, 2005.
28. 2 receptors to renal microvascular reactivity in mice. Am J Physiol Renal Physiol 283: F415-F422, 2002.
29. Ishibashi R, Tanaka I, Kotani M, Muro S, Goto M, Sugawara A, Mukoyama M, Sugimoto Y, Ichikawa A, Narumiya S, Nakao K. Roles of prostaglandin E receptors in mesangial cells under high-glucose conditions. Kidney Int 56: 589-600, 1999.
30. Jefferson JA, Shankland SJ, Pichler RH. Proteinuria in diabetic kidney disease: a mechanistic viewpoint. Kidney Int 74: 22-36, 2008.
31. Joy MS, Gipson DS, Dike M, Powell L, Thompson A, Vento S, Eddy A, Fogo AB, Kopp JB, Cattran D, Trachtman H. Phase I trial of rosiglitazone in FSGS. I. Report of the FONT Study Group. Clin J Am Soc Nephrol 4: 39-47, 2009.
32. Kanamori H, Matsubara T, Mima A, Sumi E, Nagai K, Takahashi T, Abe H, Iehara N, Fukatsu A, Okamoto H, Kita T, Doi T, Arai H. Inhibition of MCP-1/CCR2 pathway ameliorates the development of diabetic nephropathy. Biochem Biophys Res Com 360: 772-777, 2007.
33. Kanwar YS, Sun L, Xie P, Liu FY, Chen S. A glimpse of various pathogenetic mechanisms of diabetic nephropathy. Annu Rev Pathol 6: 395-423, 2011.
34. Karamouzis I, Sarafidis PA, Karamouzis M, Iliadis S, Haidich AB, Sioulis A, Triantos A, Vavatsi-Christaki N, Grekas DM. Increase in oxidative stress but not in antioxidant capacity with advancing stages of chronic kidney disease. Am J Nephrol 28: 397-404, 2008.
35. 2 receptor. Nat Med 5: 217-220, 1999.
36. 2 signaling in the renal medulla by promoting EP3 and EP4 receptor expression. Kidney Int 75: 278-284, 2009.
37. Kobori H, Kamiyama M, Harrison-Bernard Navar LM, LG. Cardinal role of the intrarenal renin-angiotensin system in the pathogenesis of diabetic nephropathy. J Investig Med 61: 256-264, 2013.
38. Kohan DE, Pritchett Y, Molitch M, Wen S, Garimella T, Audhya P, Andress DL. Addition of atrasentan to renin-angiotensin system blockade reduces albuminuria in diabetic nephropathy. J Am Soc Nephrol 22: 763-772, 2011.
39. Komers R, Lindsley JN, Oyama TT, Anderson S. Cyclo-oxygenase-2 inhibition attenuates the progression of nephropathy in uninephrectomized diabetic rats. Clin Exp Pharmacol Physiol 34: 36-41, 2007.
40. 2 promotes cellular recovery from established nephrotoxic serum nephritis in mice, prosurvival, and regenerative effects on glomerular cells. Am J Physiol Renal Physiol 304: F463-F470, 2013.
41. Lee HY, Sakuma I, Ihm SH, Goh CW, Koh KK. Statins and reninangiotensin system inhibitor combination treatment to prevent cardiovascular disease. Circ J 78: 281-287, 2014.
42. Levey AS, Coresh J. Chronic kidney disease. Lancet 379: 165-180, 2012.
43. 2 receptor agonist alleviates disease in a new mouse model of X-linked nephorgenic diabetes insipidus. J Clin Invest 119: 3115-3126, 2009.
44. Liu Y. Epithelial to mesenchymal transition in renal fibrogenesis: pathologic significance, molecular mechanism, and therapeutic intervention. J Am Soc Nephrol 15: 1-12, 2004.
45. 2 mediates proliferation and chloride secretion in ADPKD cystic renal epithelia. Am J Physiol Renal Physiol 303: F1425-F1434, 2012.
46. Makino H, Tanaka I, Mukoyama M, Sugawara A, Mori K, Muro S, Suganami T, Yahata K, Ishibashi R, Ohuchida S, Maruyama T, Narumiya S, Nakao K. Prevention of diabetic nephropathy in rats by prostaglandin E receptor EP1-selective antagonist. J Am Soc Nephrol 13: 1757-1765, 2002.
47. Miyajima A, Ito K, Asano T, Seta K, Ueda A, Hayakawa M. Does cyclooxygenase-2 inhibitor prevent renal tissue damage in unilateral ureteral obstruction? J Urol 166: 1124-1129, 2001.
48. Mohamed R, Jayakumar C, Ramesh G. Chronic administration of EP4-selective agonist exacerbates albuminuria and fibrosis of the kidney in streptozotocin-induced diabetic mice through IL-6. Lab Invest 93: 933-945, 2013.
49. Mohamed R, Jayakumar C, Ranganathan PV, Ganapathy V, Ramesh G. Kidney proximal tubular epithelial-specific overexpression of netrin-1 suppresses inflammation and albuminuria through suppression of COX-2-mediated PGE2 production in streptozotocin-induced diabetic mice. Am J Pathol 181: 1991-2002, 2012.
50. Mong MC, Yin MC. Nuclear factor κB-dependent anti-inflammatory effects of s-allyl cysteine and s-propyl cysteine in kidney of diabetic mice. J Agric Food Chem 60: 3158-3165, 2012.
51. Nair S, Wilding JP. Sodium glucose cotransporter 2 inhibitors as a new treatment for diabetes mellitus. J Clin Endocrinol Metab 95: 34-42, 2010.
52. Nakagawa N, Yuhki K, Kawabe J, Fujino T, Takahata O, Kabara M, Abe K, Kojima F, Kashiwagi H, Hasebe N, Kikuchi K, Sugimoto Y, Narumiya S, Ushikubi F. The intrinsic prostaglandin E2-EP4 system of the renal tubular epithelium limits the development of tubulointerstitial fibrosis in mice. Kidney Int 82: 158-171, 2012.
53. Nasrallah R, Clark J, Hébert RL. Prostaglandins in the kidney-developments since Y2K. Clin Sci 113: 297-311, 2007.
54. Nasrallah R, Robertson SJ, Hébert RL. Chronic COX inhibition reduces diabetes-induced hyperfiltration, proteinuria, and renal pathological markers in 36-week B6-Ins2 (Akita) mice. Am J Nephrol 30: 346-353, 2009.
55. Nasrallah R, Robertson SJ, Karsh J, Hébert RL. Celecoxib modifies glomerular basement membrane, mesangial area and podocyte structure in OVE26 mice, but ibuprofen is more detrimental. Clin Sci 124: 685-694, 2013.
56. Akita type 1 diabetic mice. Am J Physiol Renal Physiol 292: F278-F284, 2007.
57. Navarro-Gonzalez JF, Mora-Fernandez C. The role of inflammatory cytokines in diabetic nephropathy. J Am Soc Nephrol 19: 433-442, 2008.
58. Nørregaard R, Jensen BL, Li C, Wang W, Knepper MA, Nielsen S, Frøkiær J. COX-2 inhibition prevents downregulation of key renal water and sodium transport proteins in response to bilateral ureteral obstruction. Am J Physiol Renal Physiol 289: F322-F333, 2005.
59. 4 receptor in furosemide-induced salt-losing tubulopathy: a model for hyperprostaglandin E syndrome/antenatal Bartter syndrome. J Am Soc Nephrol 16: 2354-2362, 2005.
60. Ohga S, Shikata K, Yozi K, Okada S, Ogawa D, Usui H, Wada J, Shikata Y, Makino H. Thiazolidinedione ameliorates renal injury in experimental diabetic rats through anti-inflammatory effects mediated by inhibition of NF-κB activation. Am J Physiol Renal Physiol 292: F1141-F1150, 2007.
61. Okada S, Shikata K, Matsuda M, Ogawa D, Usui H, Kido Y, Nagase R, Wada J, Shikata Y, Makino H. Intercellular adhesion molecule-1-deficient mice are resistant against renal injury after induction of diabetes. Diabetes 52: 2586-2593, 2003.
62. 2 in urinary concentration? J Am Soc Nephrol 24: 169-178, 2013.
63. Ozturk H, Ozdemir E, Otcu S, Buyukbayram H, Ihsan DA. Renal effects on a solitary kidney of specific inhibition of cyclooxygenease-2 after 24 h of complete ureteric obstruction in rats. Urol Res 30: 223-226, 2002.
64. Pena-Silva RA, Heistad DD. EP1c times for angiotensin: EP1 receptors facilitate angiotensin II-induced vascular dysfunction. Hypertension 55: 846-848, 2010.
65. 4 receptor is necessary for stimulation of the renin-angiotensin-aldosterone system in response to low dietary salt intake in vivo. Am J Physiol Renal Physiol 303: F1435-F1442, 2012.
66. 2 actions in the microcirculation of rat kidney. Am J Physiol Renal Physiol 279: F755-F764, 2000.
67. 2 causes mesangial cell hypertrophy and decreases expression of cyclin D3. Nephron Physiol 113: 7-14, 2009.
68. Qian Y, Feldman E, Pennathur S, Kretzler M, Brosius FC. From fibrosis to sclerosis mechanisms of glomerulosclerosis in diabetic nephropathy. Diabetes 57: 1439-1445, 2008.
69. 1 receptor. Can J Physiol Pharmacol 84: 877-885, 2006.
70. Regner KR. Dual role of microsomal prostaglandin E synthase 1 in chronic kidney disease. Hypertension 59: 12-13, 2012.
71. Reichetzeder C, Tsuprykov O, Hocher B. Endothelin receptor antagonists in clinical research-lessons learned from preclinical and clinical kidney studies. Life Sci [Epub ahead of print].
72. 2 mediates connecting tubule glomerular feedback. Hypertension 62: 1123-1128, 2013.
73. 2, a necessary evil for cell signaling. Science 312: 1882-1883, 2006.
74. Ritz E, Wenzel RR. Endothelin antagonist as add-on treatment for proteinuria in diabetic nephropathy: is there light at the end of the tunnel? J Am Soc Nephrol 22: 593-595, 2011.
75. Rivero A, Mora C, Muros M, Garcia J, Herrera H, Navarro-Gonzalez JF. Pathogenic perspectives for the role of inflammation in diabetic nephropathy. Clin Sci 116: 479-492, 2009.
76. Ruggenenti P, Cravedi P, Remuzzi G. The RAAS in the pathogenesis and treatment of diabetic nephropathy. Nat Rev Nephol 6: 319-330, 2010.
77. 2 EP1 receptor increases arteriolar tone and blood pressure in mice with type 2 diabetes. Cardiovasc Res 83: 148-154, 2009.
78. Sanchez PL, Salgado LM, Ferreri NR, Escalante B. Effect of cyclooxygenase-2 inhibition on renal function after renal ablation. Hypertension 34: 848-853, 1999.
79. Schernthaner G. Kidney diseases beyond nephrology. Kidney disease in diabetology: lessons from 2007. Nephrol Dial Transplant 23: 1112-1115, 2008.
80. 4 receptors in mouse kidneys. Am J Physiol Renal Physiol 287: F427-F433, 2004.
81. Sedeek M, Nasrallah R, Touyz RM, Hebert RL. NADPH oxidases, reactive oxygen species and the kidney-friend and foe. J Am Soc Nephrol 24: 1512-1518, 2013.
82. Simões e Silva AC, Silveira KD, Ferreira AJ, Teixeira MM. ACE2, angiotensin-(1-7) and Mas receptor axis in inflammation and fibrosis. Br J Pharmacol 169: 477-492, 2013.
83. Singh DK, Winocour P, Farrington K. Mechanisms of isease: the hypoxic tubular hypothesis of diabetic nephropathy. Nephrology 4: 216-226, 2008.
84. Small DM, Coombes JS, Bennett N, Johnson DW, Gobe GC. Oxidative stress, anti-oxidant therapies and chronic kidney disease. Nephrology 17: 311-321, 2012.
85. Srivastava T, McCarthy ET, Sharma R, Kats A, Carlton CG, Alon US, Cudmore PA, El-Meanawy A, Sharma M. Fluid flow shear stress upregulates prostanoid receptor EP2 but not EP4 in murine podocytes. Prostaglandins Other Lipid Mediat 104: 49-57, 2013.
86. Stitt-Cavanagh EM, Faour WH, Takami K, Carter A, Vanderhyden B, Guan Y, Schneider A, Breyer MD, Kennedy CRJ. A maladaptive role for EP4 receptors in podocytes. J Am Soc Nephrol 21: 1678-1690, 2010.
87. 1 receptor mediates pain perception and regulates blood pressure. J Clin Invest 107: 325-331, 2001.
88. Suganami T, Mori K, Tanaka I, Mukoyama M, Sugawara A, Makino H, Muro S, Yahata K, Ohuchida S, Maruyama T, Narumiya S, Nakao K. Role of prostaglandin E receptor EP1 subtype in the development of renal injury in genetically hypertensive rats. Hypertension 42, 1183-1190, 2003.
89. Sugimoto Y, Namba T, Shigemoto R, Negishi M, Ichikawa A, Narumiya S. Distinct cellular localization of mRNAs for three subtypes of prostaglandin E receptor in kidney. Am J Physiol Renal Fluid Electrolyte Physiol 266: F823-F828, 1994.
90. 2 modulation of blood pressure homeostasis: studies in rodent models. Prostaglandins Other Lipid Mediat 96: 10-13, 2011.
91. 2 analogue sulprostone antagonizes vasopressin-induced antidiuresis through activation of Rho. J Cell Sci 116: 3285-3294, 2003.
92. 2 on the renal afferent arteriole. Circ Res 86: 663-670, 2000.
93. Tang LQ, Liu S, Zhang ST, Zhu LN, Wang FL. Berberine regulates the expression of E-prostanoid receptors in diabetic rats with nephropathy. Mol Biol Rep 41: 3339-3347, 2014.
94. Tang SC, Lai KN. The pathogenic role of the renal proximal tubular cell in diabetic nephropathy. Nephrol Dial Transplant 27: 3049-3056, 2012.
95. Tarabra E, Giunti S, Barutta F, Salvidio G, Burt D, Deferrari G, Gambino R, Vergola D, Pinach S, Perin PC, Camussi G, Gruden G. Effect of monocyte chemoattractant protein-1/CC chemokine receptor 2 system on nephrin expression in streptozotocin-treated mice and human cultured podocytes. Diabetes 58: 2109-2118, 2009.
96. Taslipinar A, Yaman H, Yilmaz MI, Demirbas S, Saglam M, Taslipinar MY, Agilli M, Kurt YG, Sonmez A, Azal O, Bolu E, Yenicesu M, Kutlu M. The relationship between inflammation, endothelial dysfunction, and proteinuria in patients with diabetic nephropathy. Scand J Clin Lab Invest 71: 606-612, 2011.
97. Thibodeau JF, Nasrallah R, He Y, Carter A, Touyz R, Hebert RL, Kennedy C. PTGER1 deletion attenuates renal injury in diabetic mice. Am J Pathol 183: 1789-1802, 2013.
98. Tonelli M, Wiebe N, Culleton B, House A, Rabbat C, Fok M, McAlister F, Garg AX. Chronic kidney disease and mortality risk: a systematic review. J Am Soc Nephrol 17: 2034-2047, 2006.
99. Trachtman H, Fervenza FC, Gipson DS, Heering P, Jayne DRW, Peters H, Rota S, Remuzzi G, Rump LC, Sellin LK, Heaton JPW, Streisand JB, Hard ML, Ledbetter SR, Vincenti F. A phase 1, single-dose study of fresolimumab, an anti-TGF-beta antibody, in treatment-resistant primary focal segmental glomerulosclerosis. Kidney Int 79: 1236-1243, 2011.
100. Vallon V. The proximal tubule in the pathophysiology of the diabetic kidney. Am J Physiol Regul Integr Comp Physiol 300: R1009-R1022, 2011.
101. Vallon V, Thomas SC. Renal function in diabetic disease models: the tubular system in the pathophysiology of the diabetic kidney. Annu Rev Physiol 74: 351-375, 2012.
102. 3 receptor. Am J Physiol Renal Physiol 292: F1094-F1101, 2007.
103. Villeneuve LM, Natarajan R. The role of epigenetics in the pathology of diabetic complications. Am J Physiol Renal Physiol 299: F14-F25, 2010.
104. 3 receptor regulates cyclooxygenase-2 expression in the kidney. Am J Physiol Renal Physiol 303: F449-F457, 2012.
105. 2 in acute and chronic kidney failure. Kidney Int 70: 1099-1106, 2006.
106. Wada J, Makino H. Inflammation and the pathogenesis of diabetic nephropathy. Clin Sci 124: 139-152, 2013.
107. Wang JL, Cheng HF, Shappell S, Harris RC. A selective cyclooxygenase-2 inhibitor decreases proteinuria, and retards progressive renal injury in rats. Kidney Int 57: 2334-2342, 2000.
108. Wang JL, Cheng HF, Zhang MZ, McKanna JA, Harris RC. Selective increase of cyclooxygenase-2 expression in a model of renal ablation. Am J Physiol Renal Physiol 275: F613-F622, 1998.
109. Williams ME, Garg R. Glycemic management in ESRD and earlier stages of CKD. Am J Kidney Dis 63: S22-S38, 2014.
110. 2 in tubular epithelial regeneration through inhibition of apoptosis and epithelial-mesenchymal transition in cisplatin-induced rat renal lesions. Histol Histopathol 25: 995-1007, 2010.
111. Yang X, Kume S, Tanaka Y, Isshiki K, Araki S, Chin-Kanasaki M, Sugimoto T, Koya D, Haneda M, Sugaya T, Li D, Han P, Nishio Y, Kashiwagi A, Maegawa H, Uzu T. GW501516, a PPARdelta agonist, ameliorates tubulointerstitial inflammation in proteinuric kidney disease via inhibition of TAK1-NFkB pathway in mice. PLoS One 6: e25271, 2011.
112. Yao B, Xu J, Qi Z, Harris RC, Zhang MZ. Role of renal cortical cyclooxygenase-2 expression in hyperfiltration in rats with high-protein intake. Am J Physiol Renal Physiol 291: F368-F374, 2006.
113. Yim HE, Yoo KH. Renin-angiotensin system-considerations for hypertension and kidney. Electrolyte Blood Press 6: 42-50, 2008.
114. Yokoyama U, Iwatsubo K, Umemura M, Fujita T, Ishikawa Y. The prostanoid EP4 receptor and its signaling pathway. Pharmacol Rev 65: 1010-1052, 2013.
115. Zahner G, Schaper M, Panzer U, Kluger M, Stahl RA, Thaiss F, Schneider A. Prostaglandin EP2 and EP4 receptors modulate expression of the chemokine CCL2 (MCP-1) in response to LPS-induced renal glomerular inflammation. Biochem J 422: 563-570, 2009.
116. 2 is a potent inhibitor of epithelial-to-mesenchymal transition: interaction with hepatocyte growth factor. Am J Physiol Renal Physiol 291: F1323-F1331, 2006.
117. 2 signaling. Am J Physiol Renal Physiol 302: F70-F77, 2012.
118. Zhuo JL, Li XC. New insights and perspectives on intrarenal reninangiotensin system: focus on intracrine/intracellular angiotensin II. Peptides 32: 1551-1565, 2011.
119. Ziyadeh FN. Mediators of diabetic renal disease: the case for TGF-β as the major mediator. J Am Soc Nephrol 15: S55-S57, 2004.